Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 10Breast Neoplasms 7Colorectal Neoplasms 5Prostatic Neoplasms 4Hematologic Neoplasms 4Melanoma 3Lung Neoplasms 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Malignant Solid Neoplasm 2Leukemia, Myeloid, Acute 2Hematopoietic and Lymphatic System Neoplasm 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2COVID-19 2Anatomic Stage I Breast Cancer AJCC v8 2Vaping 1Urologic Neoplasms 1Urologic Diseases 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spondylitis, Ankylosing 1Speech 1Smoking 1Seroma 1Renal Insufficiency, Chronic 1Rectal Neoplasms 1

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bilateral Breast Carcinoma × Standard of Care × 30 days × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡